Literature DB >> 32162830

Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma.

Andrew W Hahn1, Sumanta K Pal2, Neeraj Agarwal3.   

Abstract

Entities:  

Year:  2019        PMID: 32162830      PMCID: PMC7066721          DOI: 10.1634/theoncologist.2019-0657

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  10 in total

1.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.

Authors:  Nizar M Tannir; Elizabeth Plimack; Chaan Ng; Pheroze Tamboli; Nebiyou B Bekele; Lianchun Xiao; Lisa Smith; Zita Lim; Lance Pagliaro; John Araujo; Ana Aparicio; Surena Matin; Christopher G Wood; Eric Jonasch
Journal:  Eur Urol       Date:  2012-06-27       Impact factor: 20.096

2.  Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Authors:  Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George
Journal:  Lancet Oncol       Date:  2016-01-13       Impact factor: 41.316

3.  Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.

Authors:  Jad Chahoud; Pavlos Msaouel; Matthew T Campbell; Tharakeswara Bathala; Lianchun Xiao; Jianjun Gao; Amado J Zurita; Amishi Yogesh Shah; Eric Jonasch; Padmanee Sharma; Nizar M Tannir
Journal:  Oncologist       Date:  2019-09-09

4.  Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

Authors:  Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri
Journal:  Eur Urol       Date:  2015-11-26       Impact factor: 20.096

5.  Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Authors:  Nieves Martínez Chanzá; Wanling Xie; Mehmet Asim Bilen; Hannah Dzimitrowicz; Jarred Burkart; Daniel M Geynisman; Archana Balakrishnan; I Alex Bowman; Rohit Jain; Walter Stadler; Yousef Zakharia; Vivek Narayan; Benoit Beuselinck; Rana R McKay; Abhishek Tripathi; Russell Pachynski; Andrew W Hahn; JoAnn Hsu; Sumit A Shah; Elaine T Lam; Tracy L Rose; Anthony E Mega; Nicholas Vogelzang; Michael R Harrison; Amir Mortazavi; Elizabeth R Plimack; Ulka Vaishampayan; Hans Hammers; Saby George; Naomi Haas; Neeraj Agarwal; Sumanta K Pal; Sandy Srinivas; Benedito A Carneiro; Daniel Y C Heng; Dominick Bosse; Toni K Choueiri; Lauren C Harshman
Journal:  Lancet Oncol       Date:  2019-02-28       Impact factor: 41.316

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.

Authors:  Nils Kroeger; Wanling Xie; Jae-Lyn Lee; Georg A Bjarnason; Jennifer J Knox; Mary J Mackenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishamayan; Sun-Young Rha; Sumanta K Pal; Takeshi Yuasa; Frede Donskov; Neeraj Agarwal; Christian K Kollmannsberger; Min-Han Tan; Scott A North; Brian I Rini; Toni K Choueiri; Daniel Y C Heng
Journal:  Cancer       Date:  2013-05-21       Impact factor: 6.860

8.  Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.

Authors:  Matthew T Campbell; Mehmet A Bilen; Amishi Y Shah; Emily Lemke; E Jonasch; A M Venkatesan; E Altinmakas; C Duran; Pavlos Msaouel; N M Tannir
Journal:  Eur J Cancer       Date:  2018-10-28       Impact factor: 9.162

9.  The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

Authors:  Rana R McKay; Dominick Bossé; Wanling Xie; Stephanie A M Wankowicz; Abdallah Flaifel; Raphael Brandao; Aly-Khan A Lalani; Dylan J Martini; Xiao X Wei; David A Braun; Eliezer Van Allen; Daniel Castellano; Guillermo De Velasco; J Connor Wells; Daniel Y Heng; Andre P Fay; Fabio A Schutz; JoAnn Hsu; Sumanta K Pal; Jae Lyun Lee; James J Hsieh; Lauren C Harshman; Sabina Signoretti; Robert J Motzer; Darren Feldman; Toni K Choueiri
Journal:  Cancer Immunol Res       Date:  2018-05-10       Impact factor: 11.151

10.  Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Authors:  Vadim S Koshkin; Pedro C Barata; Tian Zhang; Daniel J George; Michael B Atkins; William J Kelly; Nicholas J Vogelzang; Sumanta K Pal; JoAnn Hsu; Leonard J Appleman; Moshe C Ornstein; Timothy Gilligan; Petros Grivas; Jorge A Garcia; Brian I Rini
Journal:  J Immunother Cancer       Date:  2018-01-29       Impact factor: 13.751

  10 in total
  1 in total

1.  Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.

Authors:  Naveen Kumar; Masoom Raza; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2021-07-29       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.